Lilly builds case for a third CDK4/6 inhibitor, but may struggle to differentiate late-to-market abemaciclib

11 September 2017

Eli Lilly (NYSE: LLY) has presented results at the European Society of Medical Oncology (ESMO) congress in Madrid, which look set to bolster the Indianapolis-based firm’s hopes of competing in the CDK4 and CDK6 inhibitor space with its candidate abemaciclib.

The data from the Phase III MONARCH 3 trial pitted the breast cancer candidate against placebo. All 493 enrollees had also received standard endocrine therapy.

The 18-month interim analysis showed Lilly’s option reduced the risk of disease progression by 46%, the company said. The objective response rate was 59% in the abemaciclib arm and 44% in the placebo cohort.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK